We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
NuGene International Inc (PK) | USOTC:NUGN | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0002 | 6.06% | 0.0035 | 0.0035 | 0.0051 | 0.0035 | 0.0029 | 0.0029 | 2,835,205 | 21:01:38 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 3, 2023
LIVENTO GROUP, INC.
(Exact Name of Registrant as Specified in Charter)
Nevada | 000-56457 | 46-3999052 | ||
(State
or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S.
Employer Identification No.) |
17 State Street, New York, New York 10004
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (980)432-8241
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Not applicable | Not applicable | Not applicable |
Item 1.01 Entry into a Material Definitive Agreement.
On March 3, 2023, Livento Group, Inc. (the “Company” or “Livento”) entered into a Share Purchase Agreement (the “SPA”) with the three shareholders of Novel.ti, a Tunisian corporation (“Novelti”), whereunder the Company acquired all of the shares of Novleti in exchange for 10,000,000 shares of the Company’s common stock. Novelti will operate as a subsidiary of the Company. Novelti is engaged in software development in the areas of robotics, AI and logistics and management believes that the acquisition of Novelti will allow the Company to enhance and extend its software offerings. The Company also entered into a two year consulting agreement with Novelti’s two principal officers, which among other things, includes a non-competition provision. Reference is made to the SPA and consulting agreement, which are exhibits to this Report, for the full terms and conditions thereof. Due to the size of this transaction, there is no requirement to file historical financial information with respect to Novelti.
9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit | Description | |
10.1 | Share Purchase Agreement | |
10.2 | Consulting Agreement | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 7, 2023
LIVENTO GROUP, INC. | ||
By: | /s/ David Stybr | |
Name: | David Stybr | |
Title: | Chief Executive Officer |
3 |
1 Year NuGene (PK) Chart |
1 Month NuGene (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions